Alector

CA - South SFBiotechnology1 H-1B visas (FY2023)

View 2 open jobs Website LinkedIn Careers Page

Focus: Alector is a South San Francisco-based biotechnology company focused on monoclonal antibody treatments for Alzheimer's disease and other neurodegenerative disorders. The company operates as a mid-stage biotech with a pipeline spanning Phase 1 to Phase 3 development.

Neurology

Profile data last refreshed 20h ago · AI intelligence enriched 3w ago

Open Jobs

2+1 this month

Stable — net +1 jobs in 30d

1 added, 0 removed. Backfill posture.

Should You Work at Alector?

AI assessment

Alector is a specialized, pipeline-focused neurobiotech suitable for early-career scientists and specialists seeking deep disease expertise and Phase 3 upside, but with limited hiring signals and significant financial transparency gaps.

Why Work Here

Focused therapeutic area: Alector concentrates entirely on neurodegenerative diseases with 6 programs in Phase 2 and advanced candidates, offering deep expertise building in a high-impact field.

Data completeness

2/9 — Limited

Company HealthStrong

Pipeline

Mid-stage

1 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

AL003

Alzheimer Disease

Phase 1

Clinical Trials (1)

NCT03822208First in Human Study for Safety and Tolerability of AL003.

Phase 1

Help build intelligence for Alector

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Lead program momentum: Latozinemab in Phase 3 represents a near-term catalyst for company valuation and headcount growth.

Antibody technology platform: Monoclonal antibody focus provides specialized technical skill-building in a rapidly advancing modality with broad market applicability.

Watch Out For

Minimal current hiring: Only 1 active job opening (in People/HR) signals either early-stage staffing completion or limited near-term expansion despite pipeline progress.
Pre-revenue biotech model: No commercial products and no disclosed revenue means dependence on funding cycles and milestone-driven cash flow.
Data opacity: Missing employee count, founding date, funding history, and financial metrics make it difficult to assess runway, valuation stage, and stability.

Generated by Claude from Alector's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

AL101

Healthy Volunteers

Phase 1

Clinical Trials (2)

NCT06079190Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's Disease

Phase 2

NCT04111666A Phase 1 First in Human Study to Assess Safety and Tolerability of AL101

Phase 1

AL002

Alzheimer Disease

Phase 2

Clinical Trials (3)

NCT05744401A Long-term Extension Study to Evaluate Safety, Tolerability, and Efficacy of AL002 in Alzheimer's Disease

Phase 2

NCT04592874A Phase 2 Study to Evaluate Efficacy and Safety of AL002 in Participants With Early Alzheimer's Disease

Phase 2

NCT03635047A Phase I Study for Safety and Tolerability of AL002.

Phase 1

GSK4527226

Alzheimer's Disease

Phase 2

Clinical Trials (1)

NCT07105709Open-label Extension Study in Participants With Early Alzheimer's Disease

Phase 2

AL001

Frontotemporal Dementia

Phase 2

Clinical Trials (4)

NCT04374136A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3)

Phase 3

NCT03987295A Phase 2 Study to Evaluate Safety of Long-term AL001 Dosing in Frontotemporal Dementia (FTD) Patients (INFRONT-2)

Phase 2

NCT05053035A Phase 2 Study to Evaluate AL001 in C9orf72-Associated ALS

Phase 2

+1 more

Latozinemab

Neurodegenerative Diseases

Phase 3

Clinical Trials (1)

NCT06111014Continuation Study for Latozinemab

Phase 3

Interview Prep Quick Facts

Portfolio: 12 clinical trials

Top TAs: Neurology

H-1B (2023): 1 approval

Open Roles: 2 active jobs

Therapeutic Area Focus

Neurology

10 pipeline

Marketed

Pipeline

Hiring Trend

Stable

Open Roles

Added

-0

Filled/Removed

Based on last 4 crawl cycles

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

100%

Rate

Source: USCIS H-1B Employer Data Hub

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Alector

Should You Work at Alector?

Why Work Here

Pipeline & Clinical Trials

Watch Out For

Open Jobs (2)

Associate Director, Project Management

People Operations Specialist (Part Time/Temporary)

Hiring Trend

Visa Sponsorship